Dr Reddy's gets USFDA nod for generic twice-a-year HIV prevention shot

What happened

Dr Reddy’s Laboratories said it received tentative USFDA approval for generic lenacapavir, an injectable HIV-prevention medicine taken twice a year. Under the PEPFAR pathway and a voluntary licence from Gilead Sciences, it can supply the medicine in 120 countries; initial supplies are expected before the end of 2026, with wider rollout planned for 2027.

Confirmed

Global impact / market context

The approval could give Dr Reddy’s a route into a large public-health supply opportunity and build its ability to make complex, long-acting injections. If supply begins as planned, revenue will depend on access agreements, production capacity and uptake across the licensed countries, while the planned $40 annual price may constrain revenue per patient.

Analyst inference

This is tentative approval, not confirmation that sales have begun. The article says supply is expected before the end of 2026 and broader rollout in 2027, so near-term financial contribution depends on production readiness and market access. The $40 per-patient annual price is described as planned, not realized.

Analyst inference

What to watch

1. Watch for confirmation of the first supplies before the end of 2026; delays could postpone revenue and defer evidence that manufacturing can meet expected demand. Analyst inference
2. Track the broader rollout planned for 2027 across the 120 licensed countries, including whether access arrangements and country-level procurement turn regulatory permission into actual orders. Analyst inference
3. Watch for updates to the planned $40 annual price per patient and reported production capacity; both will shape revenue potential and the cost of supplying this injection. Analyst inference

Evidence

• Original source link unavailable